{"id":"7e406008-26a7-56ae-bed7-1b5f6ad0a2c1","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-bcrp","predicate":"decreases_in_recorded_comparison","statement":"Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"13eb60ba-c7fe-5b22-8b12-3b12c383ebb3","mechanism_event_label":"Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"b3905994-0846-5a47-a94c-625c934786a2","slug":"rat-abcg2","display_name":"Rat breast cancer resistance protein / Abcg2","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"13eb60ba-c7fe-5b22-8b12-3b12c383ebb3","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-bcrp-event","event_type":"experimental_observation","label":"Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.","description":"### api-rat-bcrp\n\nApigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.\nProtein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.\nModel and exposure: Seven-day oral apigenin regimen with subsequent dasatinib exposure.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin pretreatment in the drug experiment","sequence_order":0,"notes":""},{"entity":{"id":"b3905994-0846-5a47-a94c-625c934786a2","slug":"rat-abcg2","display_name":"Rat breast cancer resistance protein / Abcg2","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"88135948-2929-586d-9c29-02e9312b99e3","slug":"dasatinib","display_name":"Dasatinib","entity_type_key":"drug"},"role":"partner drug","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin pretreatment in the drug experiment\", \"comparator\": \"Drug-only controls\", \"endpoint\": \"Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Seven-day oral apigenin regimen with subsequent dasatinib exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-rat-bcrp; Protein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ef86ddb7-cab4-56f2-ad9c-0ad1630784de","evidence_kind":"source_excerpt","locator":"Lines 896-902","start_line":896,"end_line":902,"excerpt":"### api-rat-bcrp\n\nApigenin decreased measured hepatic/intestinal Rat breast cancer resistance protein / Abcg2 expression in the rat dasatinib study.\nProtein/mRNA expression is not a transport-flux or human clinical drug-clearance measurement.\nModel and exposure: Seven-day oral apigenin regimen with subsequent dasatinib exposure.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Seven-day oral apigenin regimen with subsequent dasatinib exposure.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}